Ex-Novartis Exec Joins Checkpoint Agonist-Focused Biotech
Carolin Barth Is New CEO
The Oxford university spin-out MiroBio has a senior leadership team in place, and aims to have its first checkpoint agonists in the clinic in 2022. Scrip spoke to its CEO about its plans.
You may also be interested in...
Company is keeping its cards close to chest on exact mechanism as it enters increasingly competitive autoimmune disease field.
As rival Phase III gene therapy trials get underway, Sarepta’s product could have the edge in safety and efficacy over its rival from Pfizer, but the chance of failure remains high.
Some remain unconvinced on durability, but CRISPR Therapeutics is looking at a second ‘consolidation’ dose and other measures to boost CTX110’s efficacy in a pivotal trial.